Insight journal - Deals and alliances

Current Agreements Deal Analysis Update : June 2014

Posted on 05 June 2014

Tags: , , ,

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in May 2014.

Welcome to the June 2014 edition of Current Agreements Deals Update.

Deal of the month

Asset purchase agreement for consumer business

May 06, 2014 - Merck and Co., Bayer

Bayer has agreed to acquire the consumer care business of Merck & Co for a purchase price of USD 14.2 billion (EUR 10.4 billion)......more

Breaking news...

Asset purchase agreement for aesthetic dermatology products

May 28, 2014 - Valeant Pharmaceuticals, Nestle, Galderma

Valeant Pharmaceuticals International has entered into an agreement with Nestle to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for.....more

For more breaking deals as they are announced, visit: http://www.currentagreements.com

Month in Review

May 2014 has been yet another busy month with the announcement of many high value deals bringing the total number of deals for the month to 161 partnering deals . The top partnering deal by value was the asset purchaseagreement for the consumer business between Bayer and Merck & Co. worth $USD 14.2bn. Further details can be viewed here.

On the M&A front, 29 deals were announced; the leading deal was the acquisition of CFR Pharmaceuticals by Abbott Laboratories in a deal valued at $USD 3.3bn. Further details can be viewed here.

On the financings front we recorded 80 announcements, with the leading deal by value being the equity repurchase for $USD 5bn by Gilead Sciences. Further details can be viewed here.

Our sister company, Current Partnering published several new and updated reports:

View our full list of reports here at our report store.

Our Current Partnering website showcases the leading partnering, M&A and financing deals by value.

To see all of 2014 leading deals and view the full set of Scorecards for 2014, visit  Partnering scorecard  | M&A scorecard | Financing scorecard - check them out.

We welcome your comments and feedback on this newsletter. We are also interested in hearing from any company with a deal not announced by press release; this allows us to add non-publicized deals to the database.

Best regards,

Shamini Thiagarajan

Top ten deal analysis of the month by deal value

The following are the top 10 partnering deals and alliances by value, as announced in May 2014.

1. Asset purchase agreement for consumer business - Bayer, Merck and Co - $14.2bn

2. Collaboration agreement for sGC modulation- Bayer, Merck and Co- $2.1bn

3. Asset purchase agreement for aesthetic dermatology products-  Galderma, Nestle, Valeant Pharmaceuticals- $1.4bn

4. Licensing and market agreement for Fovista- Novartis, Ophthotech - $1.03bn

5. Settlement and cross-licensing agreement for $750 million with Edwards Lifesciences - Edwards Lifesciences, Medtronic - $750m

6. Settlement agreement for $650 million for Pradaxa - Boehringer Ingelheim - $650m

7. Collaborative R&D and licensing agreement for gene therapy products - Avalanche Biotechnologies, Regeneron Pharmaceuticals - $640m

8. Asset purchase agreement for ophthalmology products- Merck and Co, Santen Pharmaceutical - $600m

9. Option agreement for the development and licensing of MGD010 - Macrogenics, Takeda Pharmaceutical - $501.5m

10. Asset purchase agreement for Interventional Division of Bayer - Bayer, Boston Scientific - $415m

Full details of each deal available at Current Agreements*
*Subscription required

Big pharma deal analysis May 2014

May saw 40 partnering deals announced with big pharma being at least one of the parties of the deal.

Merck & Co. were particularly active, leading partnering activities in May.

Merck & Co partnering- May 2014

  • Collaboration agreement for companion diagnostic test for analysis of tumor biomarker PD-L1 -with Dako
  • Asset purchase agreement for microbial process development and manufacturing operations -with KBI BioPharma
  • Asset purchase agreement for ophthalmology products - with Santen Pharmaceutical
  • Asset purchase agreement for consumer business -with Bayer
  • Collaboration agreement for sGC modulation - with Bayer

Merck & Co partnering interests

Merck & Co profile

Merck & Co partnering report

Further details of all big pharma deals are available at Current Agreements.

Big biotech deal analysis May 2014

May saw 8 partnering deals announced with big biotech being at least one of the parties of the deal.

Biogen Idec were particularly active, leading partnering activity in May.

Biogen Idec partnering- May 2014

  • Collaboration agreement for drug discovery for autoimmune disorder - with Array Biopharma
  • Collaboration agreement for educating multiple sclerosis patients - with Sailing Sclerosos Foundation
  • Collaboration agreement for donating Clotting factor units to third world nations - with Swedish Orphan Biovitrum

Biogen Idec partnering interests

Biogen Idec profile

Biogen Idec partnering report

Further details of all big pharma deals are available at Current Agreements.

Current Agreements products

CP Knowledge Centre : Access the best of Current Partnering and Current Agreements with a CP Knowledge Center subscription. Buy now

 

Print Friendly, PDF & Email

Leave a Reply

 

cabannerad300x150new4gif
rauconbadgejpg
e80banner300x150animgif
cpbannerad300x150new2gif
rauconbadgejpg
a1banner300x150animgif